Navigation Links
China Shenghuo Pharmaceutical Reports Financial Results for the Full Year 2011
Date:3/30/2012

KUNMING, China, March 30, 2012 /PRNewswire/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" or the "Company"), today reported financial results for the year ended December 31, 2011.

Full Year 2011 Highlights

  • Total revenue was approximately $44.2 million, an increase of 35% from approximately $32.7 million for the year 2010.
  • Gross profit as a percentage of revenues was approximately 61.5%, as compared to 65.8 % in 2010.
  • Net income attributable to stockholders was approximately $0.1 million, as compared to approximately $1.2 million for the year ended December 31, 2010.
  • The stockholder's equity was approximately $2.1 million as of December 31, 2011.

  • Full Year 2011 ResultsSales: Sales for the year ended December 31, 2011 were approximately $44.2 million, an increase of approximately $11.5 million, or 35%, from approximately $32.7 million for the year ended December 31, 2010. The increase in sales was primarily due to the Company's main product Xuesaitong's sales increasing in Tianjin City, Jiangsu, Guangdong and Yunnan Province as Xuesaitong was listed on the PIC list of Tianjin City since the second half year in 2010 and the Company strengthened sales promotion in the provinces and cities where Xuesaitong was listed on their PIC lists, especially Yunnan Province and Tianjin City. The OTC market also contributed part of increase of revenue as the Company also strengthened the OTC market development in 2011.

    Cost of sales: Our cost of sales for the year ended December 31, 2011 was approximately $17.0 million, an increase of approximately $5.8 million, or 52%, from approximately $11.2 million for the year ended December 31, 2010. The increase in cost of sales was due to the increase of the sales volume and the purchase price of Sanqi which is the main raw material of our main product Xuesaitong. Although we have started to grow Sanqi within the Resort, we will not be able to harvest until 2014 because it has a three year growth cycle. In addition, the Zhonghuang Hotel began trial operation since January 2011 which has contributed $2.3 million to the increase of cost of sales.

    Gross profit: Our gross profit for the year ended December 31, 2011 was approximately $27.2 million as compared with approximately $21.5 million for the year ended December 31, 2010. Gross profit as a percentage of revenues was approximately 61.5% for the year ended December 31, 2011, a decrease of 4.3% from 65.8 % for the year ended December 31, 2010. The decrease in gross profit percentage was primarily due to the increase of cost of sales set forth above.

    Selling expenses: Selling expenses were approximately $19.8 million for the year ended December 31, 2011, an increase of approximately $4.1 million, or 26%, from approximately $15.7 million for the year ended December 31, 2010. The primary reason for the increase in selling expenses was due to increase of sales commission to sales representative in line with the sales increment.

    We reimburse the sales representatives their selling and marketing expenses when they submit the appropriate documentation to be reimbursed. We reimburse the sales representatives their accrued selling expenses when related accounts receivable are collected.

    General and administrative expenses: General and administrative expenses were approximately $5.0 million for the year ended December 31, 2011, an increase of approximately $1.4 million, or 38%, from approximately $3.6 million for the year ended December 31, 2010. The increase was primarily due to the increase of the management's traveling expenses and conference expenses for expanding our sales channel. In addition, Zhonghuang Hotel began trial operation since January 2011 which has contributed approximately $0.5 million to the increase of general and administrative expense.

    Research and development expenses: Research and development expense for the year ended December 31, 2011 was approximately $0.71 million as compared to approximately $0.66 million for the year ended December 31, 2010. The increase was primarily due to the expenditures in 2011 for the Phase I clinical test of Sh1002 in America which amounted to $303,335.

    Net other expense: Net other expense, which includes interest income, subsidy income, interest expense, other income and other expense, was approximately $1.5 million for the year ended December 31, 2011 as compared to approximately $0.1 million for the year ended December 31, 2010, an increase of approximately $1.4 million, or 1323%. The increase was mainly due to less subsidy income from provincial government as compared the same period in 2010 and more interest expenses in the 2011.

    Income tax benefit (expense): Income tax benefit was $11,765 for the year ended December 31, 2011 as compared to income tax expense $105,764 for the year ended December 31, 2010. The tax benefit was mainly from medicine segment of the Company and the deferred tax assets benefit from accrued expenses and provisions for inventory.

    Net income attributable to stockholders: We achieved a net income attributable to stockholders of approximately $0.1 million for the year ended December 31, 2011 as compared to approximately $1.2 million for the year ended December 31, 2010. The decrease in net income attributable to stockholders was primarily due to the decrease of subsidy income and increase of interest expense.

    About China ShenghuoFounded in 1995, China Shenghuo is primarily engaged in the research, development, manufacture, and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which is currently being listed in the 2010 Provincial Insurance Catalogue of sixteen provinces around China. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Singapore, Japan, Malaysia, and Thailand and to European countries such as the United Kingdom, Tajikistan, Russia and Kyrgyzstan.

    With the substantial completion of Shenghuo Plaza at the end of 2010, China Shenghuo entered into a new business -- the hotel and hospitality business. Two floors of Shenghuo Plaza are designed to be utilized as 12 Ways Chinese Herbal Beauty Demonstration Center. The balance of Shenghuo Plaza is used as a business hotel -- Zhonghuang Hotel, restaurant and banquet facilities and an entertainment venue.

    China Shenghuo is also expanding into the businesses of wellness tourism. For more information, please visit http://www.shenghuo.com.cn.

    Safe Harbor StatementThis press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's ability to refinance or repay loans received; the Company's uncertain business condition; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; risks arising from potential weaknesses or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Company Contact:China Shenghuo Pharmaceutical Holdings, Inc.Ms. Shujuan WangSecretary of Board of Directors +86-871-7282698CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(Amounts in USD, except shares)December 31,20112010Assets:Current assets:   Cash and cash equivalents$

    1,247,230$

    1,669,387   Restricted cash794,115-   Accounts and notes receivable, net18,076,05011,531,027   Other receivables, net4,084,1024,111,315   Advances to suppliers, net542,153580,168   Inventories2,695,3882,599,351   Amounts due from related parties574,899190,614   Current deferred tax assets1,394,101833,568   Other current assets199,929208,111Total current assets29,607,96721,723,541   Property, plant and equipment, net 25,873,67021,069,139   Intangible assets, net 1,473,0741,432,736   Deposits for long-live assets1,078,846754,979   Non-current deferred tax assets275,677366,478Total assets$

    58,309,234$

    45,346,873CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS (CONT'D)(Amounts in USD, except shares)December 31,20112010Liabilities and Equity:Current liabilities:   Accounts payable$9,395,483

    $

    8,964,404   Other payables and accrued expenses11,819,1799,699,857   Sales representative deposits6,106,2874,936,429   Amounts due to related parties18,41479,864   Short-term borrowings15,858,8955,289,178   Advances from customers1,090,6681,158,649   Taxes and related payables2,255,322881,506   Current portion of long-term borrowings6,253,0756,039,833Total current liabilities52,797,32337,049,720Long-term borrowings-6,251,227Total liabilities52,797,32343,300,947Commitments and ContingenciesEquity:   Common stock, $0.0001 par value, 100,000,000 sharesauthorized and 19,679,400 shares issued and outstanding1,9681,968   Additional paid-in capital6,014,6886,193,927   Appropriated retained earnings147,023147,023   Accumulated deficit(5,790,759)(5,940,439)   Accumulated other comprehensive income1,743,3931,638,109Total stockholder's equity2,116,3132,040,588Non-controlling interest3,395,5985,338Total equity5,511,9112,045,926Total liabilities and equity$

    58,309,234$

    45,346,873CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE INCOME (LOSS)(Amounts in USD, except shares)Years ended December 31,20112010Sales $

    44,158,182$

    32,697,195Cost of goods sold16,980,00611,198,736Gross profit27,178,17621,498,459Operating expenses:   Selling expenses19,838,58215,715,325   General and administrative expenses5,015,5343,638,445   Research and development expense710,361656,22525,564,47720,009,995Income from operations1,613,6991,488,464Other income (expenses):   Interest income11,8108,325   Subsidy income536,013786,916   Interest expense(1,714,887)(842,560)   Other income82,712247,536   Other expenses(409,405)(305,185)(1,493,757)(104,968)Income before income tax119,9421,383,496Income tax benefit (expense) 11,765(105,764)Net income before allocation to non-controlling interests131,7071,277,732Less: net (loss) income attributable to non-controlling interests(17,973)60,878Net income attributable to stockholders$149,680$1,216,854Comprehensive income:Net income 131,7071,277,732   Foreign currency translation adjustment187,15051,517Comprehensive income $318,857$1,329,249Comprehensive income attributable to  non-controlling interests63,89363,333Comprehensive income attributable to stockholders254,9641,265,916Basic and diluted earnings per share$

    0.01$

    0.06Weighted-average number of shares outstanding  - basic and diluted19,679,40019,679,400CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(Amounts in USD)Years ended December 31,20112010Cash Flows from Operating Activities:Net income

    $

    131,707$

    1,277,732Adjustments to reconcile net income to net cash provided by operating activities:   Deferred income tax(398,459)58,362   Depreciation and amortization1,494,985755,380   Bad debt provision and allowance and inventories write off380,8251,786,315   Gain on disposal of fixed assets-(103,140)Change in working capital:   Accounts and notes receivable(5,980,478)799,195   Other receivables233,5851,234,888   Amounts due from/to related parties(365,393)313,278   Advances to suppliers(88,842)(168,759)   Inventories(22,393)1,164,966   Other current assets18,351(186,754)   Accounts payable(26,097)1,935,119   Other payables and accrued expenses1,584,229(713,701)   Advances from customers(124,047)207,968   Sales representative deposits895,308(2,277,841)   Taxes and related payables1,296,310(242,273)Net Cash (Used in) Provided by Operating Activities(970,409)5,840,735Cash Flows from Investing Activities:Purchase of long-lived assets(2,299,690)(8,354,461)Proceeds from disposal of long-lived assets4,753317,679Net Cash Used in Investing Activities(2,294,937)(8,036,782)Cash Flows from Financing Activities:Increase in restricted cash(794,115)-Contribution from non-controlling interests-29,539Proceeds from borrowings25,897,07629,582,155Payments on borrowings(22,352,041)(27,791,252)Net Cash Provided by Financing Activities 2,750,9201,820,442Effect of exchange rate fluctuation on cash and cash equivalents92,26958,452Net decrease in cash and cash equivalents(422,157)(317,153)Cash and cash equivalents at beginning of year1,669,3871,986,540Cash and cash equivalents at end of year$

    1,247,230$

    1,669,387Supplemental Information:Cash paid for interest

    $

    1,540,896$

    967,686Cash paid for income tax

    $

    71,503$

    130,229Non-cash activity:Contribution from non-controlling interests3,199,273-
    '/>"/>

    SOURCE China Shenghuo Pharmaceutical
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
    2. Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform
    3. Fi Asia-China, Hi & Ni China is Ready for Return on June 2012 in Shanghai
    4. China Botanic Reports First Quarter Fiscal 2012 Results
    5. Medical Device Market in China 2011-2015
    6. Compression Therapy Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
    7. China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results
    8. Respiratory Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
    9. QIAGEN Expands Access to State-of-the-art HPV Screening in China Through Co-marketing Agreement With KingMed Diagnostics
    10. EntreMed Initiates Plans for China Office
    11. China Kanghui Holdings to Report Fourth Quarter and Full Year 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... 12, 2016   National Community Pharmacists Association ... issued the following statement today in response to the ... the Centers for Medicare & Medicaid Services (CMS) and ... advocates and others: patient advocacy organizations ... reviewing the full CMS analysis. Our initial reaction is ...
    (Date:2/12/2016)... 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in ... Okaloosa County Emergency Medical Services (EMS) consisting ... one LT2 van. Quality Emergency Vehicles in Lecanto, ... the sale.  This is the latest in Demers, ongoing expansion ... President at Demers. --> Benoit LaFortune , Executive ...
    (Date:2/12/2016)... , Feb. 12, 2016  Memorial Hermann Health ... Dwight Howard to bring a one-of-a-kind experience ... . Using cutting-edge technologies such as 360-degree video and ... both virtually, then literally – giving the patients and ... and it was all caught on video . ...
    Breaking Medicine Technology:
    (Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... In the ... forward. They’ll groom themselves to perfection, go out of their way to be romantic, ... – just take a look at any online dating profile. , A recent ...
    (Date:2/12/2016)... , ... February 12, 2016 ... ... today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced ... will recruit top students from U.S. universities who will draw from Siemens’ ...
    (Date:2/12/2016)... Los Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... be. With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz ... there, she dedicated herself to meditation for its impact on her life, implementing a ...
    (Date:2/12/2016)... ... , ... Every winter, someone is killed, injured or loses a home in ... part of the Allegheny Health Network, has partnered with Etna Volunteer Fire Department, ... Space” campaign. , “Space Heaters Need Space” aims to bring awareness to ...
    (Date:2/12/2016)... , ... February 12, 2016 , ... Erlanger Agency has ... greater Columbus, OH area. The latest campaign focuses on the fight against breast cancer, ... are now being accepted here . , Carmen is a loving single mother ...
    Breaking Medicine News(10 mins):